Technical Analysis for DMPI - DelMar Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade C 1.06 22.54% 0.20
DMPI closed up 22.54 percent on Friday, June 5, 2020, on 3.73 times normal volume.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Up
Historical DMPI trend table...

Date Alert Name Type % Chg
MACD Bullish Signal Line Cross Bullish 0.00%
Pocket Pivot Bullish Swing Setup 0.00%
Volume Surge Other 0.00%
Wide Range Bar Range Expansion 0.00%
Wide Bands Range Expansion 0.00%
Up 3 Days in a Row Strength 0.00%
Calm After Storm Range Contraction 22.54%
NR7 Range Contraction 22.54%
NR7-2 Range Contraction 22.54%
Wide Bands Range Expansion 22.54%

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

DelMar Pharmaceuticals, Inc. is a clinical-stage drug development company. The Company focuses on the treatment of cancer. The Company is engaged in conducting clinical trials in the United States with its product candidate, VAL-083, as a treatment for glioblastoma multiforme (GBM), a form of brain cancer. VAL-083 is being evaluated in a Phase II clinical trial for the treatment of refractory GBM. In addition to its clinical development activities in the United States, the Company has obtained certain commercial rights to VAL-083 in China where it is approved as a chemotherapy for the treatment of chronic myelogenous leukemia (CML) and lung cancer. Its drug discovery research focuses on identifying validated clinical and commercial-stage compounds, and establishing a scientific rationale for development in orphan drug indications. VAL-083 is an alkylating agent, which crosses the blood-brain-barrier (BBB).
Medicine Cancer Clinical Medicine Treatment Of Cancer Oncology Drug Discovery Cancer Treatments Chemotherapy Drug Development Antineoplastic Drugs Leukemia Glioblastoma Brain Tumor Lung Cancer Brain Cancer Glioblastoma Multiforme

Is DMPI a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 2.66
52 Week Low 0.38
Average Volume 418,403
200-Day Moving Average 0.60
50-Day Moving Average 0.63
20-Day Moving Average 0.82
10-Day Moving Average 0.93
Average True Range 0.11
ADX 42.84
+DI 37.16
-DI 11.90
Chandelier Exit (Long, 3 ATRs ) 0.82
Chandelier Exit (Short, 3 ATRs ) 0.88
Upper Bollinger Band 1.09
Lower Bollinger Band 0.55
Percent B (%b) 0.95
BandWidth 65.31
MACD Line 0.09
MACD Signal Line 0.09
MACD Histogram 0.0025
Fundamentals Value
Market Cap 22.84 Million
Num Shares 21.6 Million
EPS -0.74
Price-to-Earnings (P/E) Ratio -1.43
Price-to-Sales 0.00
Price-to-Book 77.27
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.41
Resistance 3 (R3) 1.37 1.23 1.35
Resistance 2 (R2) 1.23 1.14 1.24 1.33
Resistance 1 (R1) 1.14 1.08 1.19 1.18 1.31
Pivot Point 1.00 1.00 1.02 1.01 1.00
Support 1 (S1) 0.91 0.91 0.96 0.95 0.81
Support 2 (S2) 0.77 0.85 0.78 0.79
Support 3 (S3) 0.68 0.77 0.77
Support 4 (S4) 0.72